fig1

Figure 1. Potential mechanisms by which PCSK9 inhibition protects against CVD independently of LDL cholesterol lowering. Inhibition of PCSK9 affects cellular responses in bone marrow derived cells (monocytes/macrophages, DCs, T cells and platelets), ECs and VSMCs in the artery wall, and cardiomyocytes, which might all contribute to cardioprotective effects mediated by inhibition of PCSK9. Figure created with BioRender.com. CVD: Cardiovascular disease; LDL: low-density lipoprotein; DCs: dendritic cells; ECs: endothelial cells; VSMCs: vascular smooth muscle cells